Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Pie Chart with COPCOV recruitment as of 7th July 2021. A black & white version of the pie chart and a table with figures can be found at https://www.tropmedres.ac/news/recruitment-surges-in-copcov-covid-19-prevention-study/copcov-recruitment-as-of-7-july-2021

COPCOV – the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19 – has more than doubled recruitment in the past month, with 1332 participants enrolled as of 7 July. Funded by Wellcome and led by MORU, COPCOV has begun recruitment in Benin, Côte d'Ivoire, Indonesia and Mali, restarted in Pakistan and Zambia, and hopes to open new study sites in Benin, Ethiopia, Guatemala, Indonesia, Kenya, Nepal and Niger.

This is truly fantastic and demonstrates the determination and support of all those involved in the study, and in particular our collaborators at sites.

Sponsored by the University of Oxford (UK) and led by the Bangkok-based Mahidol Oxford Tropical Medicine Research Unit (MORU), COPCOV (Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19)) is funded by a grant by the COVID-19 Bill & Melinda Gates Foundation, Wellcome and MasterCard Therapeutics Accelerator.

However, timelines are tight if COPCOV is to answer the question as to whether chloroquine/ hydroxychloroquine prevents COVID-19. As the last-standing large prophylaxis RCT, the COPCOV study is in the unique position of being able to still give the answer definitively. Now, more than ever, with the end in sight, we need one last push from all!

Since COPCOV began recruitment in Thailand in April of 2020, the COVID-19 landscape has changed considerably. Vaccination has gone from a distant hope, to a reality for many but not all, and yet COVID-19 daily cases are some of the highest they have ever been worldwide. In addition, highly transmissible mutants have established themselves and overwhelmed countries which had previously dealt well with outbreaks. Mutants against which there is decreased vaccine efficacy are also here, and we should expect these to become more prevalent as vaccines apply selective pressure. Now, as before, effective chemotherapeutics could still be lifesaving to prevent and treat infections and maybe much more so, if we do see these mutants causing vaccine failures.

Recently it has been stated that the evidence suggests the drugs do not work. Most notably the WHO’s   A living guideline on drugs to prevent covid-19 stated that there was high certainty evidence that hydroxychloroquine does not prevent COVID-19.

This is wrong with large amounts of uncertainty in the effect which hydroxychloroquine may have in prevention. and with the effect estimate of currently published studies pointing towards moderate benefit. Truthfully, we still don’t know. While there is this uncertainty, and COVID-19 continues to infect people around the world, we must continue. We have responded to these articles, have a letter upcoming to The Lancet, pointing out their flaws, and have received strong support to continue from all those involved in the study and our excellent Trial Steering Committee and Data Safety and Management Board to continue.

Our thanks to everyone for their continued support and hard work, in what have been very challenging circumstances. Now more than ever, this study is needed, and with the recent increased recruitment, success is once again in our sights!

- Nick White and Will Schilling, COPCOV co-PIs.

For accessibility, we have posted a black & white version of the pie chart, and a table with all figures

Similar stories

Antibiotic accountability: how countries and companies perform

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.

New! A learning framework about antimicrobial resistance for children and young people

A downloadable resource for educators, health & research professionals to help develop young peoples’ understanding of AMR and positive actions they can take to mitigate it.

Overusing antibiotics? Find out with Antibiotic Footprint Calculator

To mark WHO World Antimicrobial Awareness Week, 18-24 Nov 2021, and help reduce the overuse of antibiotics, MORU researchers have released a new, easy to use online tool – Antibiotic Footprint Calculator – that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world’s most significant emerging threats to public health.

GRAM study provides the first longitudinal estimates of global antibiotic consumption in 204 countries from 2000 to 2018

Global antibiotic consumption rates increased by 46 percent in the last two decades, according to the first study to provide longitudinal estimates for human antibiotic consumption covering 204 countries from 2000 to 2018, published in Lancet Planetary Health by the Global Research on Antimicrobial Resistance (GRAM) Project.

Rise in COPCOV numbers continues; study to end recruitment 30 Nov

A global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV has recruited 3,386 participants as of 26 Oct from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, and closed sites in Thailand, Niger and the UK. Last week, the COPCOV team agreed with active site research teams that it will continue to recruit new participants until 30 Nov 2021, with preliminary study results expected Q1 2022.

Large-scale systematic review identifies research gaps in scrub typhus

A new, extensive systematic review has identified significant research gaps in the treatment of scrub typhus which could be improved by developing a database for individual participant data (IPD) to enable more detailed analyses to address important knowledge gaps such as the optimum dosing for children and to improve patient outcomes.